Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.
Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.
The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan compared with placebo in the treatment of decompensated chronic heart failure.
Inclusion Criteria:
Exclusion Criteria:
The following criteria would exclude the patient from study:
Washington D.C., District of Columbia 20010, United States
New York, New York 10003, United States
Philadelphia, Pennsylvania 19102, United States
Concord, New South Wales NSW 2139, Australia
Zrifin, 70300, Israel